MA52888A - Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques - Google Patents
Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiquesInfo
- Publication number
- MA52888A MA52888A MA052888A MA52888A MA52888A MA 52888 A MA52888 A MA 52888A MA 052888 A MA052888 A MA 052888A MA 52888 A MA52888 A MA 52888A MA 52888 A MA52888 A MA 52888A
- Authority
- MA
- Morocco
- Prior art keywords
- therapeutic agents
- benzene sulfonamide
- sulfonamide compounds
- compounds
- benzene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684436P | 2018-06-13 | 2018-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52888A true MA52888A (fr) | 2021-04-21 |
Family
ID=67138087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052888A MA52888A (fr) | 2018-06-13 | 2019-06-13 | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10745392B2 (fr) |
| EP (1) | EP3807281A1 (fr) |
| JP (2) | JP7371029B2 (fr) |
| KR (1) | KR20210019507A (fr) |
| CN (1) | CN112262142B (fr) |
| AU (1) | AU2019285184B2 (fr) |
| BR (1) | BR112020024729A2 (fr) |
| CA (1) | CA3103600A1 (fr) |
| CL (1) | CL2020003197A1 (fr) |
| CR (1) | CR20200613A (fr) |
| EA (1) | EA202092719A1 (fr) |
| EC (1) | ECSP20079861A (fr) |
| IL (1) | IL278949B1 (fr) |
| JO (1) | JOP20200304A1 (fr) |
| MA (1) | MA52888A (fr) |
| MX (1) | MX2020013317A (fr) |
| NI (1) | NI202000098A (fr) |
| PE (1) | PE20211389A1 (fr) |
| PH (1) | PH12020552111A1 (fr) |
| SA (1) | SA520420768B1 (fr) |
| SG (1) | SG11202011862PA (fr) |
| UA (1) | UA127024C2 (fr) |
| WO (1) | WO2019241533A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912216VA (en) * | 2016-05-20 | 2020-02-27 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| PE20211066A1 (es) | 2018-08-31 | 2021-06-09 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| ATE227120T1 (de) | 1997-05-07 | 2002-11-15 | Galen Chemicals Ltd | Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen |
| CA2349832A1 (fr) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek |
| DE19907385A1 (de) | 1999-02-20 | 2000-08-24 | Boehringer Ingelheim Pharma | Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine |
| KR20020016899A (ko) | 1999-07-16 | 2002-03-06 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 억제제를 사용한 만성 동통의 치료 방법 |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| WO2004002481A1 (fr) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
| JP2005162726A (ja) | 2003-01-24 | 2005-06-23 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物およびその製法 |
| WO2004092123A2 (fr) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibiteurs d'invasion fongique |
| WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
| WO2005005421A1 (fr) | 2003-07-08 | 2005-01-20 | Novartis Ag | Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes |
| PE20050358A1 (es) | 2003-08-08 | 2005-05-16 | Vertex Pharma | Composiciones referidas a inhibidores de canales ionicos regulados por voltaje |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| JP2008524244A (ja) | 2004-12-17 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | 水酸化ステロイド脱水素酵素阻害剤 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2007039171A1 (fr) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzène sulfonamides, procédés pour leur préparation et leur utilisation en tant que substances pharmaceutiques |
| WO2007075895A2 (fr) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Derives heterocycliques utilises comme modulateurs de canaux ioniques |
| CA2658960A1 (fr) | 2006-08-15 | 2008-02-21 | Alfred Binggeli | Derives phenyliques, de la pyridine et de la quinoleine |
| AU2007309468B2 (en) | 2006-10-19 | 2012-05-17 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| JP5460589B2 (ja) | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| JP5463285B2 (ja) | 2007-07-13 | 2014-04-09 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| WO2009013171A2 (fr) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Composés antiviraux hétérocycliques |
| WO2009099177A1 (fr) | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | Dérivé d'amino-imidazole |
| KR20110027657A (ko) | 2008-06-25 | 2011-03-16 | 다이이찌 산쿄 가부시키가이샤 | 카르복실산 화합물 |
| CN102099356A (zh) | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
| WO2010029300A1 (fr) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Composés bis-aromatiques pour utilisation dans le traitement de l’inflammation |
| RS53941B1 (en) | 2009-01-12 | 2015-08-31 | Pfizer Limited | SULFONAMID DERIVATIVES |
| JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| JP5749341B2 (ja) | 2010-08-20 | 2015-07-15 | ハチソン メディファーマ リミテッド | ピロロピリミジン化合物およびその使用 |
| JP2014521749A (ja) | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | ヘテロアリールナトリウムチャネル阻害剤 |
| AU2012328561A1 (en) | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013122897A1 (fr) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline |
| IN2014MN02574A (fr) | 2012-05-22 | 2015-07-24 | Genentech Inc | |
| EP2906558B1 (fr) | 2012-10-15 | 2020-09-02 | Daewoong Pharmaceutical Co., Ltd. | Bloqueurs de canal sodique, leur procédé de préparation et leur utilisation |
| CA2891056A1 (fr) | 2012-10-26 | 2014-05-01 | Merck Sharp & Dohme Corp. | Composes indazole sulfonamide n-substitues ayant une activite selective dans les canaux sodiques potentiel-dependants |
| CA2889378A1 (fr) | 2012-10-26 | 2014-05-01 | Merck Sharp & Dohme Corp. | Composes benzoxazolinone ayant une activite selective dans les canaux sodiques potentiel-dependants |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| WO2015035278A1 (fr) | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | Modulateurs de rorγ |
| RU2016113156A (ru) | 2013-09-10 | 2017-10-16 | Хромоселл Корпорейшн | Модуляторы натриевого канала для лечения боли и диабета |
| MX2016006936A (es) | 2013-11-27 | 2016-10-05 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas. |
| WO2015077905A1 (fr) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Composés de benzènesulfonamide à substitution bicycloamine ayant une activité sélective dans les canaux sodiques sensibles à la tension |
| AU2014370407B2 (en) | 2013-12-23 | 2018-03-29 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2016177340A1 (fr) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | Dérivé de benzènesulfonamide substitué bicyclique, et procédé de préparation et utilisation pharmaceutique de celui-ci |
| AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| WO2017165204A1 (fr) | 2016-03-22 | 2017-09-28 | Merck Sharp & Dohme Corp. | Composés de n1-phénylpropane-1,2-diamine ayant une activité sélective dans des canaux sodiques sensibles à la tension |
| SG10201912216VA (en) | 2016-05-20 | 2020-02-27 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| US10836758B2 (en) | 2016-10-27 | 2020-11-17 | Bristol-Myers Squibb Company | Acyl sulfonamide NaV1.7 inhibitors |
| US10968210B2 (en) * | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| WO2020047312A1 (fr) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| PE20211066A1 (es) | 2018-08-31 | 2021-06-09 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos |
-
2019
- 2019-06-13 US US16/440,459 patent/US10745392B2/en active Active
- 2019-06-13 PE PE2020001990A patent/PE20211389A1/es unknown
- 2019-06-13 CR CR20200613A patent/CR20200613A/es unknown
- 2019-06-13 AU AU2019285184A patent/AU2019285184B2/en active Active
- 2019-06-13 KR KR1020217000602A patent/KR20210019507A/ko unknown
- 2019-06-13 JP JP2020568796A patent/JP7371029B2/ja active Active
- 2019-06-13 SG SG11202011862PA patent/SG11202011862PA/en unknown
- 2019-06-13 MX MX2020013317A patent/MX2020013317A/es unknown
- 2019-06-13 EP EP19735024.2A patent/EP3807281A1/fr active Pending
- 2019-06-13 MA MA052888A patent/MA52888A/fr unknown
- 2019-06-13 CA CA3103600A patent/CA3103600A1/fr active Pending
- 2019-06-13 EA EA202092719A patent/EA202092719A1/ru unknown
- 2019-06-13 IL IL278949A patent/IL278949B1/en unknown
- 2019-06-13 WO PCT/US2019/037011 patent/WO2019241533A1/fr unknown
- 2019-06-13 CN CN201980039029.1A patent/CN112262142B/zh active Active
- 2019-06-13 BR BR112020024729-4A patent/BR112020024729A2/pt unknown
- 2019-06-13 UA UAA202008102A patent/UA127024C2/uk unknown
- 2019-12-13 JO JOP/2020/0304A patent/JOP20200304A1/ar unknown
-
2020
- 2020-07-13 US US16/927,178 patent/US11325902B2/en active Active
- 2020-12-09 PH PH12020552111A patent/PH12020552111A1/en unknown
- 2020-12-09 CL CL2020003197A patent/CL2020003197A1/es unknown
- 2020-12-10 SA SA520420768A patent/SA520420768B1/ar unknown
- 2020-12-10 EC ECSENADI202079861A patent/ECSP20079861A/es unknown
- 2020-12-10 NI NI202000098A patent/NI202000098A/es unknown
-
2023
- 2023-08-08 JP JP2023129150A patent/JP2023138672A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020552111A1 (en) | 2021-08-02 |
| CA3103600A1 (fr) | 2019-12-19 |
| JP2021528387A (ja) | 2021-10-21 |
| US20200361927A1 (en) | 2020-11-19 |
| ECSP20079861A (es) | 2021-03-31 |
| JP7371029B2 (ja) | 2023-10-30 |
| PE20211389A1 (es) | 2021-07-27 |
| EP3807281A1 (fr) | 2021-04-21 |
| SA520420768B1 (ar) | 2022-08-30 |
| AU2019285184A1 (en) | 2021-01-28 |
| BR112020024729A2 (pt) | 2021-03-23 |
| CN112262142B (zh) | 2023-11-14 |
| AU2019285184B2 (en) | 2023-11-16 |
| EA202092719A1 (ru) | 2021-03-16 |
| CL2020003197A1 (es) | 2021-04-30 |
| CN112262142A (zh) | 2021-01-22 |
| JP2023138672A (ja) | 2023-10-02 |
| US11325902B2 (en) | 2022-05-10 |
| NI202000098A (es) | 2021-05-28 |
| IL278949A (en) | 2021-01-31 |
| WO2019241533A1 (fr) | 2019-12-19 |
| KR20210019507A (ko) | 2021-02-22 |
| US20190382398A1 (en) | 2019-12-19 |
| UA127024C2 (uk) | 2023-03-15 |
| SG11202011862PA (en) | 2020-12-30 |
| IL278949B1 (en) | 2024-04-01 |
| MX2020013317A (es) | 2021-04-13 |
| JOP20200304A1 (ar) | 2020-11-25 |
| CR20200613A (es) | 2021-06-10 |
| US10745392B2 (en) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48583A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
| MA52888A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
| MA53489A (fr) | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques | |
| MA53172A (fr) | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| MA55198A (fr) | Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA49017A (fr) | Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MA53377A (fr) | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 | |
| MA50045A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA56183A (fr) | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MA53089A (fr) | Thiophènecarboxamides et analogues substitués utilisés en tant qu'agents antibactériens | |
| MA52244A (fr) | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| MA51224A (fr) | Composés de sulfonamide et leur utilisation | |
| MA53488A (fr) | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA50041A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
| MA53479A (fr) | Composés hétérocycliques en tant q'inibiteurs de vanin | |
| MA46896A (fr) | Composés d'alcène tétrasubstitués et leur utilisation | |
| MA53014A (fr) | Composés améliorant l'activité du protéasome |